AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 31 min read$KMTS

Mahboob Vaseem sold $418K of KMTS

Mahboob Vaseem (Chief Financial Officer) sold 18,188 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.99 ($22.61–$23.80, $0.42M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Mahboob Vaseem
Published Aug 3, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The only disclosed new fact is the CFO’s open-market sale details and post-transaction holdings; there is no accompanying corporate event or performance update.

02

Market read

Traders may briefly reassess sentiment around KMTS due to insider selling, but the filing lacks fundamental catalysts.

03

What to watch

The filing does not state motivations, and the sale window spans multiple days with a modest post-sale holding count; traders should avoid extrapolating company deterioration from one transaction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-03 after-hours; reflects trades dated 2026-07-30 to 2026-08-03

Background

The article is a SEC Form 4 insider transaction for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) by its CFO.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

KMTS CFO Mahboob Vaseem sold $418,217 of KMTS shares in open-market trades from 2026-07-30 to 2026-08-03.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on insider activity or company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction, but it does not include new company performance, guidance, or deal information. The absence of a stated 10b5-1 plan can raise scrutiny, yet the disclosed size is not clearly market-moving on its own.

Market effects

Sector

Minimal; insider selling in a single medical technology name does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; without additional context, the signal may be overstated.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction was filed.

  • insider
    Mahboob Vaseem

    Chief Financial Officer of KMTS who sold shares via open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min